Responsible life sciences research for global health security

A GUIDANCE DOCUMENT



Responsible life sciences research for global health security **A GUIDANCE DOCUMENT**



© World Health Organization 2010

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Designed by minimum graphics Printed by the WHO Document Production Services, Geneva, Switzerland

Contents

Ac	Acknowledgements				
Acronyms					
De	Definitions				
Ex	ecu	tive summary	1		
		roduction	3		
		Context, purpose, audience and scope of the guidance	3		
		1.1.1 Context	3		
		1.1.2 Purpose and audience	5		
		1.1.3 Scope of the guidance: WHA55.16 and the biorisk management framework for responsible			
		life sciences research	5		
	1.2	Methodology	7		
		1.2.1 Terminology	7		
	1.3	Structure of the guidance	8		
2.	Rev	view of experiments and policy options	9		
	2.1	Examples of experiments of concern	9		
		2.1.1 Accidentally increasing the virulence of mousepox as part of an experiment to control mice			
		as pests in Australia	9		
		2.1.2 Variola virus immune evasion design	9		
		2.1.3 Chemical synthesis of poliovirus cDNA	10		
		2.1.4 Reconstruction of the 1918 flu virus	10		
		2.1.5 Creating and synthesizing <i>de novo</i> organisms	11		
	2.2	Review of policy options	12		
		2.2.1 Research oversight mechanisms	12		
		2.2.2 Policies of funding agencies, publishers and editors	14		
		2.2.3 Selected national laws and regulations on research oversight and biosafety and	15		
		laboratory biosecurity	15		
		2.2.4 Codes of conduct and ethics programmes and initiatives2.2.5 Educational and training initiatives to raise awareness	17 17		
	<u>ז</u> כ	Remarks	18		
2					
э.		e biorisk management framework for responsible life sciences research Pillar 1: Research excellence	20 21		
	5.1	3.1.1 Health research systems	21		
		3.1.2 Implementing the WHO strategy on research for health	23		
		3.1.3 International Health Regulations (IHR)	23		
	32	Pillar 2: Ethics	23		
	5.2	3.2.1 Ethical considerations	24		
		3.2.2 Towards an ethics framework	25		
		3.2.3 Remarks	28		
	3.3	Pillar 3: Biosafety and laboratory biosecurity	29		
		3.3.1 Elements of biosafety and laboratory biosecurity	29		
		3.3.2 Biosafety, laboratory biosecurity and responsible life sciences	31		

_						
	way forward: the self-assessment questionnaire	32				
	Using the self-assessment tool	32				
	Interpreting the results of the self-assessment tool	32				
4.3	The self-assessment questionnaire	34				
Refere	References					
Annexe	25	45				
Annex 1. Contributors						
Annex 2	. Declaration of interests	48				
Annex 3. Guidelines review group workshop on responsible life science research, WHO, Geneva, 22–24 June 20						
Annex 4. The NSABB's proposed framework for the oversight of dual-use research						
	Annex 5. A decision-making tool from the Centre for Applied Philosophy and Public Ethics, Australia					
Annex 6	Annex 6. A model from the Center for International and Security Studies					
Annex 7.	Implementation of oversight mechanisms	57				
	. Codes of conduct	58				
Annex 9	. WHO strategy on research for health	60				
List of	figures, tables and boxes					
	The biorisk spectrum and biorisks reduction measures	6				
-	Biorisk management framework for responsible life sciences research	7				
•		10				
Table 1	Key questions and concerns	19				
Box 1	Accidentally increasing the virulence of mousepox as part of an experiment to control mice as pests	9				
Box 2	Variola virus immune evasion design	10				
Box 3	Chemical synthesis of poliovirus cDNA	10				
Box 4	Reconstruction of the 1918 flu virus	11				
Box 5	Creating and synthesizing a minimal organism	11				
Box 6	Main policy options	12				
Box 7	Fink report's seven classes of experiments	13				
Box 8	Joint agreement by BBSRC, MRC and Wellcome Trust to modify their respective policies and					
	procedures in four areas	14				
Box 9	Three pillars of a biorisk management framework for responsible life sciences research	20				
Box 10	Hallmarks for effective management policies on responsible life sciences research	21				
Box 11	Key considerations when implementing the biorisk management framework for responsible life sciences					
	research	21				
Box 12	Four core functions of a health research system	22				
Box 13	Four selected goals of the WHO strategy on research for health	24				
Box 14	Summary of research excellence elements for responsible life sciences	24				
Box 15	Key ethical questions for consideration	25				
Box 16	Summary of ethics elements for responsible life sciences research	29				
Box 17	Elements of laboratory biorisk management system	30				
Box 18	Summary of laboratory elements for responsible life sciences	31				

Acknowledgements

This guidance was prepared by Dr Emmanuelle Tuerlings (WHO department on Global Alert and Response), with the close collaboration of Dr Chandre Gould (Institute for Security Studies, Hoekwil, South Africa) and Dr Michael Selgelid (Centre for Applied Philosophy and Public Ethics (CAPPE), WHO Collaborating Centre for Bioethics, Australian National University), who respectively worked on the self-assessment questionnaire and on the ethics section. This guidance was edited by Ms Joanne McManus.

We would like to acknowledge the essential contributions of the members of the Guidelines review group on responsible life science research:

Professor Peter Ian Folb (University of Cape Town, South Africa); Dr David Franz (Midwest Research Institute, United States of America); Dr Chandre Gould (Institute for Security Studies, South Africa); Professor Raymond Lin (Ministry of Health, Singapore); Dr Amy P. Patterson (National Institutes of Health, United States of America); Dr Michael Selgelid (Centre for Applied Philosophy and Public Ethics (CAPPE), Australia); Dr Oyewale Tomori (Redeemer's University, Nigeria); Dr Lei Zhang (Chinese Academy of Sciences, China). We would also acknowledge the vital input of the Chair of Guidelines review group on responsible life science research, Professor Peter Folb, who over the years, provided insightful, precious and constructive advice on the project and on this guidance. No conflict of interests were declared by members of the Guidelines review group on responsible life science research (Annex 2).

We would also like to acknowledge the important written comments and critiques made by the reviewers on previous drafts of this document:

Mrs Elisa D. Harris (Center for International and Security Studies at Maryland School of Public Policy, University of Maryland, United States of America); Professor Li Huang (Chinese Academy of Sciences and the InterAcademy Panel Biosecurity Working Group, China); Dr Jo Husbands (National Academy of Sciences, United States of America); Professor John S. Mackenzie (Curtin University of Technology, Australia); Dr Caitriona McLeish (Science and Technology Policy Research, University of Sussex, United Kingdom); Dr Piers Millett (BWC Implementation Support Unit, United Nations, Switzerland); Professor Kathryn Nixdorff (Darmstadt University of Technology, Germany); Dr Amy P. Patterson and staff of the Office of Biotechnology Activities (National Institutes of Health, United States of America); Professor Janusz T. Paweska (National Institute for Communicable Diseases of the National Health Laboratory Service, South Africa); Professor Ian Ramshaw (National Centre for Biosecurity, Australia); Dr Brian Rappert (University of Exeter, United Kingdom); Professor Julian Perry Robinson (Science and Technology Policy Research, University of Sussex, United Kingdom); Dr Stefan Wagener (National Microbiology Laboratory, Winnipeg, Public Health Agency of Canada).

In addition, we would like to acknowledge the support of WHO staff Mrs Zerthun Alemu Belay, Mr James Atkinson, Dr May Chu, Dr Ottorino Cosivi, Dr Ana Estrela, Dr Pierre Formenty, Dr Ali Mohammadi, Mrs Lily Laryea, Dr Matthew Lim, Dr Tikki Pang, Dr Carmem Pessoa Da Silva, Dr Nicoletta Previsani, Dr Andreas Reis, Dr Cathy Roth and Dr Michael Ryan in this project as well as the constructive comments made by the WHO Guidelines Review Committee.

Finally, we would like to acknowledge the financial support provided by the Alfred P. Sloan Foundation and the Ford Foundation that has made the development and production of this guidance possible.

Acronyms

BSL	Biosafety level
BWC	Biological and Toxin Weapons Convention
BBSRC	Biotechnology and Biological Sciences Research Council (United Kingdom)
CDC	Centers for Disease Control and Prevention of the Department of Health and Human Serv- ices (United States of America)
CSE	Council of Science Editors
EC	European Commission of the European Union
GMO	Genetically modified organism
IAP	InterAcademy Panel
ICLS	International Council for the Life Sciences
ICSU	International Council for Science
IHR	International Health Regulations
IUBMB	International Union of Biochemistry and Molecular Biology
IUMS	International Union of Microbiological Societies
HRS	Health research systems
MRC	Medical Research Council (United Kingdom)
NGO	Nongovernmental organization
NIH	National Institutes of Health of the Department of Health and Human Services (United States of America)
NRC	National Research Council of the National Academies (United States of America)
NSABB	National Science Advisory Board for Biosecurity (United States of America)
PHEIC	Public Health Emergencies of International Concern
rDNA	Recombinant DNA
RS	Royal Society of the United Kingdom
VBM	Valuable biological materials
WAME	World Association of Medical Editors
WHA	World Health Assembly of the World Health Organization
WHO	World Health Organization

Definitions

The following terms are defined in the context in which they are used in this document.

- **Bioethics** The study of the ethical and moral implications of biological discoveries, biomedical advances and their applications, as in the fields of genetic engineering and drug research (1).¹
- **Biological laboratory** A facility within which biological agents, their components or their derivatives, and toxins are collected, handled and/or stored. Biological laboratories include clinical laboratories, diagnostic facilities, regional and national reference centres, public health laboratories, research centres (academic, pharmaceutical, environmental, etc.) and production facilities (the manufacturing of vaccines, pharmaceuticals, large-scale genetically modified organisms, etc.) for human, veterinary and agricultural purposes (1).
- **Biorisk** The risk (risk is a function of likelihood and consequences) that a particular biological event (in the context of this document: naturally occurring diseases, accidents, unexpected discovery, or deliberate misuse of biological agents and toxins), which may affect adversely the health of human populations, may occur (1, 2).

- **Laboratory biosafety** The containment principles, technologies and practices that are implemented to prevent unintentional exposure to biological agents and toxins, or their accidental release (*3*, *4*).
- **Laboratory biosecurity** The protection, control and accountability for valuable biological materials² within laboratories, in order to prevent their unauthorized access, loss, theft, misuse, diversion or intentional release (1).
- **Dual-use life sciences research** Knowledge and technologies generated by legitimate life sciences research that may be appropriated for illegitimate intentions and applications (*2*, *5*).
- Life sciences All sciences that deal with organisms, including humans, animals and plants, and including but not limited to biology, biotechnology, genomics, proteomics, bioinformatics, pharmaceutical and biomedical research and techniques.
- **Global health security** The activities required, both proactive and reactive, to minimize vulnerability to acute public health events that endanger the collective health of populations living

预览已结束, 完整报告链接和二维码如下:

https://www.yunbaogao.cn/report/index/report?reportId=5 29098

